Saama

Models do the substantive work across the lifecycle: automating data quality review and query generation, writing and testing the code for cross domain checks, and generating regulatory submission artifacts. The company reports over 90 to 100 specialized models trained specifically for life sciences rather than adapting general models, which is the differentiating claim.

The company names its own autonomy level, which almost nobody in this index does. Its Clinical AI Agents are stated to function on partial autonomy explicitly designed to enable appropriate human oversight and controls, while being capable of independent reasoning, planning, and execution. Publishing a deliberate ceiling, rather than describing maximum capability and leaving the limit implicit, is the right disclosure in a regulated context where trial data integrity is auditable and submission artifacts carry regulatory consequence.

Model count and training scope are stated, over 90 to 100 models trained on life sciences data reported in the hundreds of millions of data points, and the agent framework architecture is described as modular and integrable with existing sponsor platforms rather than requiring replacement. Held back from A because no model cards, benchmark results, or validation methodology were retrieved, which matters more here than usual since submission artifacts generated by these models enter regulatory filings.

Deployment scale is substantial and long standing: more than 1,500 studies across over 50 pharma and biotech companies, with the company stating its platform supported the trial behind the first COVID-19 vaccine. Customer attributed results with Pfizer are specific and cover distinct workflows rather than one headline: query handling reduced roughly 90 percent, data transformation roughly 50 percent, and submission timelines roughly 35 percent. Investor composition is itself corroborating, with Amgen, Merck, Pfizer, and McKesson venture arms all participating, meaning several large customers put capital behind the platform.

No public pricing. Contact the vendor. Enterprise agreements with pharmaceutical and biotech sponsors, sold both as platform SaaS and as customized solutions and services. Buyers should establish the split, since a services heavy engagement prices and scales very differently from platform licensing.

Clearly bounded to sponsor side clinical development from study start through regulatory submission, spanning data management, quality, patient insights, and submission generation. The company is explicit that it also serves other industries with general data services, and this record covers the health sciences platform only.